Desthiazolylmethyl Ritonavir
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H574658

CAS#: 256328-82-2

Description: Desthiazolylmethyl ritonavir is a base-catalyzed degradation product of ritonavir.

Chemical Structure

img
Desthiazolylmethyl Ritonavir
CAS# 256328-82-2
Instruction

Theoretical Analysis

Hodoodo Cat#: H574658
Name: Desthiazolylmethyl Ritonavir
CAS#: 256328-82-2
Chemical Formula: C33H43N5O4S
Exact Mass: 605.30
Molecular Weight: 605.800
Elemental Analysis: C, 65.43; H, 7.15; N, 11.56; O, 10.56; S, 5.29

Price and Availability

Size Price Availability Quantity
10mg USD 300 2 Weeks
25mg USD 650 2 Weeks
50mg USD 1050 2 Weeks
Bulk inquiry

Synonym: Ritonavir EP Impurity L, Ritonavir specified impurity L [EP], Ritonavir Impurity L

IUPAC/Chemical Name: (2S)-N-[(2S)-1-[(4S,5S)-4-benzyl-2-oxo-1,3-oxazolidin-5-yl]-3-phenylpropan-2-yl]-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanamide

InChi Key: YIFUFODEQQNFLV-AMEOFWRWSA-N

InChi Code: InChI=1S/C33H43N5O4S/c1-21(2)29(37-32(40)38(5)19-26-20-43-31(35-26)22(3)4)30(39)34-25(16-23-12-8-6-9-13-23)18-28-27(36-33(41)42-28)17-24-14-10-7-11-15-24/h6-15,20-22,25,27-29H,16-19H2,1-5H3,(H,34,39)(H,36,41)(H,37,40)/t25-,27-,28-,29-/m0/s1

SMILES Code: CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2C(NC(=O)O2)CC3=CC=CC=C3)CC4=CC=CC=C4

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 605.80 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Rojas J, Lonca M, Imaz A, Estrada V, Asensi V, Miralles C, Domingo P, Montero
M, Del Rio L, Fontdevila J, Perez I, Cruceta A, Gatell JM, Arnedo M, Martínez E.
Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir.
HIV Med. 2016 May;17(5):340-9. doi: 10.1111/hiv.12314. Epub 2015 Sep 10. PubMed
PMID: 27089862.

2: Yang W, Xiao Q, Wang D, Yao C, Yang J. Evaluation of pharmacokinetic
interactions between long-acting HIV-1 fusion inhibitor albuvirtide and
lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and
simulation results. Xenobiotica. 2016 Apr 6:1-11. [Epub ahead of print] PubMed
PMID: 27052428.

3: Shiffman ML, Rustgi V, Bennett M, Forns X, Asselah T, Planas Vila R, Liu L,
Pedrosa M, Moller J, Reau N. Safety and Efficacy of
Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in
HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J
Gastroenterol. 2016 Apr 5. doi: 10.1038/ajg.2016.108. [Epub ahead of print]
PubMed PMID: 27045929.

4: Pandie M, Wiesner L, McIlleron H, Hughes J, Siwendu S, Conradie F, Variava E,
Maartens G. Drug-drug interactions between bedaquiline and the antiretrovirals
lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant
TB. J Antimicrob Chemother. 2016 Apr;71(4):1037-40. doi: 10.1093/jac/dkv447. Epub
2016 Jan 7. PubMed PMID: 26747099.

5: Menon RM, Klein CE, Podsadecki TJ, Chiu YL, Dutta S, Awni WM. Pharmacokinetics
and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C
virus treatment, with and without ritonavir in healthy volunteers. Br J Clin
Pharmacol. 2016 May;81(5):929-40. doi: 10.1111/bcp.12873. Epub 2016 Feb 24.
PubMed PMID: 26710243.

6: Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H,
Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L,
Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group.
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial:
raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus
darunavir/ritonavir as first-line ART. J Antimicrob Chemother. 2016
Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24. PubMed PMID:
26702926.

7: Lee FJ, Marriott D, Bloch M, Richardson R, Mackenzie N, Carr A. Post-prandial
lipid effects of raltegravir versus darunavir/ritonavir in HIV-1-infected adults
commencing combination ART. J Antimicrob Chemother. 2016 Apr;71(4):1127-9. doi:
10.1093/jac/dkv436. Epub 2015 Dec 18. PubMed PMID: 26682962.

8: Borges ÁH, Lundh A, Tendal B, Bartlett JA, Clumeck N, Costagliola D, Daar ES,
Echeverría P, Gisslén M, Huedo-Medina TB, Hughes MD, Huppler Hullsiek K, Khabo P,
Komati S, Kumar P, Lockman S, MacArthur RD, Maggiolo F, Matteelli A, Miro JM, Oka
S, Petoumenos K, Puls RL, Riddler SA, Sax PE, Sierra-Madero J, Torti C, Lundgren
JD. Non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted
protease inhibitor-based regimens for initial treatment of HIV infection: a
systematic review and meta-analysis of randomised trials. Clin Infect Dis. 2016
Apr 18. pii: ciw236. [Epub ahead of print] PubMed PMID: 27090986.

9: Slama L, Landman R, Assoumou L, Benalycherif A, Samri A, Joly V, Pialoux G,
Valin N, Cabié A, Duvivier C, Lambert-Niclot S, Marcelin AG, Peytavin G,
Costagliola D, Girard PM; IMEA 040 DATA Study Group. Efficacy and safety of
once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual
nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive
patients with severe immunosuppression: a 48 week, non-comparative, randomized,
multicentre trial (IMEA 040 DATA trial). J Antimicrob Chemother. 2016 Apr 10.
pii: dkw103. [Epub ahead of print] PubMed PMID: 27068399.

10: Łucejko M, Parfieniuk-Kowerda A, Flisiak R. Ombitasvir/paritaprevir/ritonavir
plus dasabuvir combination in the treatment of chronic HCV infection. Expert Opin
Pharmacother. 2016 Apr 11. [Epub ahead of print] PubMed PMID: 27064432.

11: Gane EJ, Rouzier R, Hassanein T, Stedman CA, Mazur W, Kupcova V, Le Pogam S,
Eng S, Voulgari A, Morcos PN, Brennan BJ, Scalori A, Thommes J. Ritonavir-boosted
danoprevir-based regimens in treatment-naive and prior null responders with HCV
genotype 1 or 4 and compensated cirrhosis. Hepatol Int. 2016 May;10(3):478-87.
doi: 10.1007/s12072-015-9699-9. Epub 2016 Feb 17. PubMed PMID: 26886127.

12: LaFountaine JS, Jermain SV, Prasad LK, Brough C, Miller DA, Lubda D, McGinity
JW, Williams RO 3rd. Enabling thermal processing of ritonavir-polyvinyl alcohol
amorphous solid dispersions by KinetiSol® Dispersing. Eur J Pharm Biopharm. 2016
Apr;101:72-81. doi: 10.1016/j.ejpb.2016.01.018. Epub 2016 Feb 6. PubMed PMID:
26861929.

13: Calderón MM, Penzak SR, Pau AK, Kumar P, McManus M, Alfaro RM, Kovacs JA.
Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone
Concentrations in HIV-Infected Subjects. Clin Infect Dis. 2016 Apr
15;62(8):1036-42. doi: 10.1093/cid/ciw028. Epub 2016 Jan 20. PubMed PMID:
26797214; PubMed Central PMCID: PMC4803107.

14: Khatri A, Dutta S, Wang H, Podsadecki T, Trinh R, Awni W, Menon R. Evaluation
of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir,
Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors. Clin Infect
Dis. 2016 Apr 15;62(8):972-9. doi: 10.1093/cid/civ1213. Epub 2016 Jan 5. PubMed
PMID: 26740513.

15: Dickinson L, Winston A, Boffito M, Khoo S, Back D, Siccardi M. Simulation of
the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and
dose adjustment strategies: a population pharmacokinetic approach. J Antimicrob
Chemother. 2016 Apr;71(4):1041-5. doi: 10.1093/jac/dkv439. Epub 2015 Dec 27.
PubMed PMID: 26712906.

16: Saab S, Gonzalez YS, Huber C, Wang A, Juday T. Cost-effectiveness of
Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver
Transplant Recurrent Genotype 1 HCV. Liver Int. 2016 Apr;36(4):515-21. doi:
10.1111/liv.13033. Epub 2015 Dec 25. PubMed PMID: 26610059.

17: van Lunzen J, Pozniak A, Gatell JM, Antinori A, Klauck I, Serrano O, Baakili
A, Osiyemi O, Sevinsky H, Girard PM. Brief Report: Switch to Ritonavir-Boosted
Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1
Infection: A Randomized Pilot Study. J Acquir Immune Defic Syndr. 2016 Apr
15;71(5):538-43. doi: 10.1097/QAI.0000000000000904. PubMed PMID: 26605505; PubMed
Central PMCID: PMC4804741.

18: Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M,
Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA,
Gatell JM, García F; MARAVIPEP Study Group. A randomized clinical trial comparing
ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus
emtricitabine for post-exposure prophylaxis for HIV infection. J Antimicrob
Chemother. 2016 Mar 18. pii: dkw048. [Epub ahead of print] PubMed PMID: 26994091.

19: Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M,
Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA,
Gatell JM, García F; RALPEP Study Group. A randomized clinical trial comparing
ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus
emtricitabine for post-exposure prophylaxis for HIV infection. J Antimicrob
Chemother. 2016 Mar 18. pii: dkw049. [Epub ahead of print] PubMed PMID: 26994089.

20: Kao JH, Tung SY, Lee Y, Thongsawat S, Tanwandee T, Sheen IS, Wu JJ, Li H,
Brennan BJ, Zhou J, Le Pogam S, Najera I, Thommes JA, Hill G. Ritonavir-boosted
danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C
patients with or without cirrhosis. J Gastroenterol Hepatol. 2016 Mar 19. doi:
10.1111/jgh.13374. [Epub ahead of print] PubMed PMID: 26992248.